| Literature DB >> 21654973 |
Giuseppina Messina1, Stefania Anania, Claudia Bonomo, Laura Veneroni, Antonietta Andreoli, Francesca Mameli, Chiara Ortolina, Paola De Fabritiis, Maria Gaffuri, Francesco Imbesi, Egidio Moja.
Abstract
BACKGROUND: It has been shown that the pineal gland plays a fundamental role in mediating either the spiritual perception or the anticancer immunity by stimulating the endogenous production of anticancer cytokine interleukin (IL)-2.Entities:
Keywords: Cancer; spirituality; yoga
Year: 2011 PMID: 21654973 PMCID: PMC3099100 DOI: 10.4103/0973-6131.78181
Source DB: PubMed Journal: Int J Yoga ISSN: 0973-6131
Clinical characteristics of patients
| Total | SC | SCY | SCMLT | SCMLTY | SCIL2MLT | SCIL2MLTY | |
|---|---|---|---|---|---|---|---|
| Numbers | 240 | 40 | 40 | 40 | 40 | 40 | 40 |
| Gender | |||||||
| Males | 146 | 24 | 25 | 24 | 25 | 24 | 24 |
| Female | 94 | 16 | 15 | 16 | 15 | 16 | 16 |
| Age | |||||||
| Range | 34-71 | 40-70 | 34-63 | 37-69 | 35-68 | 35-70 | 34-71 |
| Median | 60 | 45 | 47 | 48 | 53 | 51 | 52 |
| Tumor histotype | |||||||
| NSCLC | 175 | 30 | 28 | 29 | 30 | 28 | 30 |
| Gi | 65 | 10 | 11 | 12 | 11 | 11 | 10 |
SC – Supportive care, SCY – Supportive care plus Yoga, MLT – Melatonin, MLTY – Melatonin plus Yoga, IL2 MLT – Interleukin–2 plus melatonin, IL2MLTY – Interleukin– 2 plus Melatonin plus Yoga), NSCLC – Non–small–cell lung cancer
Percent of survival at the end of 1 and 2 years in the different groups
| Groups | Survival time | |
|---|---|---|
| 1 Year | 2 Years | |
| SC | 1/40 (3) | 0 |
| SCY | 2/40 (5) | 0 |
| SCMLT | 10/40 (25) | 1/40 (3) |
| SCMLTY | 15/40 (38) | 3/40 (8) |
| SCIL2MLT | 21/40 (53) | 6/40 (15) |
| SCIL2MLTY | 29/40 (72) | 9/40 (25) |
P<0.001 vs SC; P<0.005 vs SCMLT, vs SCYOGA; P<0.01 vs SCMLTY; P<0.05 vs SCIL2MLT, SC – Supportive care, SCY – Supportive care plus yoga), MLT – Melatonin, MLTY – Melatonin plus yoga, IL2 MLT – Interleukin-2 plus melatonin, IL2MLTY – Interleukin–2 plus Melatonin plus Yoga, Figures in parentheses are in percentage
Figure 11-year survival curves achieved in metastatic cancer patients who failed to respond to standard anticancer therapies in relation to the type of therapeutic spiritual program
Tumor response according to WHO criteria in 240 metastatic cancer patients, who failed to respond to standard anticancer therapies, in relation to the type of therapeutic spiritual program
| Therapeutic | Clinical response | |||||
|---|---|---|---|---|---|---|
| approach | CR | PR | RR(CR+PR) | SD | DC(CR+PR+SD) | PD |
| SC | 0 | 0 | 0 (0) | 2 | 2 (5) | 38 |
| SCY | 0 | 0 | 0 (0) | 5 | 5 (13) | 35 |
| SCMLT | 0 | 0 | 0 (0) | 9 | 9 (22) | 31 |
| SCMLTY | 0 | 1 | 1 (3) | 11 | 12 (30) | 28 |
| SCIL2MLT | 0 | 5 | 5 (13) | 17 | 22 (55) | 18 |
| SCIL2MLTY | 0 | 8 | 8 (20) | 24 | 32(80) | 8 |
P<0.05 vs SCIL2MLT; P<0.025 vs SCMLTY; P<0.01 vs SCMLT; P<0.005 vs SCY; P<0.001 vs SC
CR– Complete response; PR – Partial response; SD – Stable disease; DC – Disease control; PD – progressive disease, Figures in parentheses are in percentage